Bedrijfsoverzicht
Mainz Biomed N.V. is a specialized entity focused on the development and commercialization of in-vitro diagnostic (IVD) tests designed for the early detection of cancer within the United States and European markets. The company's product portfolio primarily features ColoAlert, a molecular genetic stool test for colorectal cancer, alongside PancAlert, which is being developed as a stool-based screening solution for pancreatic cancer. Operating within the Healthcare sector and specifically the Diagnostics & Research industry, the firm leverages its 19 employees to pursue technological advancements in genetic screening and diagnostic methodologies. With a current market capitalization of $10.56M and reported annual revenue of $659,935, the company maintains a micro-cap status that reflects its position as a small-scale biotechnology developer rather than an established revenue generator. These valuation figures indicate that the company is in a high-risk, high-potential phase where market value is driven largely by intellectual property potential and future product pipeline expectations rather than current profitability or cash flow generation.
Financiële gezondheid
The company reported revenue of $659,935 for the trailing twelve months, yet this income is overshadowed by a net income loss of $18,971,112, revealing a severe cost structure where operating expenses significantly exceed total revenue generation. EBITDA stands at $-16,145,343, further highlighting the substantial burn rate required to sustain research and development activities before achieving commercial scalability. Free cash flow is negative at $-8,186,486, indicating that the company is consuming its available cash reserves to fund operations and development efforts without generating sufficient operational cash to cover these outflows. Gross margin remains robust at 67.5%, suggesting that the cost of goods sold for their diagnostic tests is well-controlled relative to sales, while operating margin is drastically negative at -2822.1%, pointing to high administrative, R&D, and selling expenses that are not yet offset by sales volume. Profit margin is recorded at 0.0%, which aligns with the negative net income and confirms that the company is currently operating at a loss on every dollar of revenue generated. On the balance sheet side, cash holdings of $1.91M are insufficient to cover total debt obligations of $3.09M, and the debt-to-equity ratio of 122.65 indicates a highly leveraged financial position relative to shareholder equity. The current ratio of 0.52 demonstrates that current assets do not cover current liabilities, signaling potential short-term liquidity pressures and a reliance on external financing or equity issuance to meet near-term obligations. Return on Equity is listed as N/A due to the lack of positive equity returns, while Return on Assets stands at -114.4%, indicating that the asset base is generating negative returns for the shareholders.
Waarderingsbeoordeling
The trailing P/E ratio is N/A because the company is currently unprofitable, whereas the forward P/E is listed as -1.14, implying that market expectations do not foresee immediate profitability within the next twelve months based on current pricing models. The price-to-book ratio is 1.37, which suggests that the market values the company at a premium of 37% over its tangible book value, likely reflecting the perceived value of its intangible assets such as patents and proprietary diagnostic technology. Price-to-sales stands at 16.01, a metric often used for unprofitable growth companies, indicating that investors are paying a significant multiple of revenue for the potential future cash flows expected from the IVD product pipeline. The EV/EBITDA ratio is -0.27, reinforcing the valuation challenge associated with negative earnings and the need for alternative valuation metrics like P/S or P/B when traditional multiples are unavailable or negative. The stock has traded between a 52-week low of $0.55 and a 52-week high of $5.34, creating a wide trading range that reflects significant price volatility typical of small-cap biotech firms. Without a specific current price provided in the facts, the trading range illustrates the substantial variance in investor sentiment and the speculative nature of the security within this volatile sector. The beta value is 0.32, indicating that the stock price exhibits low volatility relative to the broader market and tends to move less than the overall market index during periods of fluctuation.
Growth & Income
Revenue growth year-over-year has contracted to -44.9%, showing a significant decline in sales performance, while earnings growth is N/A due to the absence of positive earnings history. The decline in revenue suggests that the company is facing challenges in market penetration or product adoption that are outpacing any potential growth in its pipeline, and the negative earnings growth is consistent with the company's ongoing losses. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, meaning that all available earnings are theoretically retained, although in this case, the earnings are negative, so no cash is available for distribution. This non-dividend profile indicates that the company reinvests its limited resources, or rather, its equity base, into research and development efforts rather than distributing income to shareholders, a common strategy for early-stage biotechnology firms. The overall growth and income profile for Mainz Biomed NV is characterized by negative revenue momentum, a lack of current profitability, and no income generation through dividends, positioning the stock purely as a speculative vehicle dependent on future product success to reverse its current financial trajectory.